secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000939767-23-000112
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q3 revenue up 15% to $471.9M but GAAP net income drops to $1.0M from $73.2M
--------------------------------------------------------------------------------

- Q3 total revenues $471.9M (up 14.6% YoY); net product rev $426.5M (up 16.4% YoY).
- GAAP net income $1.0M ($0.00 EPS) vs $73.2M ($0.23 EPS) in Q3 2022; non-GAAP net income $32.1M ($0.10 EPS).
- R&D expenses surged to $332.6M from $198.8M, driven by license/collaboration costs and pipeline investments.
- Positive phase 3 data from CONTACT-02 (prostate) and CABINET (neuroendocrine tumors) studies for cabozantinib.
- Appointed Dr. Amy Peterson as CMO in August; in-licensed XL309 (USP1 inhibitor) from Insilico Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000112/0000939767-23-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000112/exel-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000939767-23-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer